Target Price | €52.25 |
Price | €45.03 |
Potential |
16.03%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target ASR Nederland 2025 .
The average ASR Nederland target price is €52.25.
This is
16.03%
register free of charge
€60.00
33.24%
register free of charge
€46.00
2.15%
register free of charge
|
|
A rating was issued by 15 analysts: 13 Analysts recommend ASR Nederland to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ASR Nederland stock has an average upside potential 2025 of
16.03%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion € | 12.65 | 7.75 |
141.60% | 38.76% | |
Net Margin | 9.68% | 12.42% |
51.99% | 28.29% |
7 Analysts have issued a sales forecast ASR Nederland 2024 . The average ASR Nederland sales estimate is
This results in the following potential growth metrics:
9 ASR Nederland Analysts have issued a net profit forecast 2024. The average ASR Nederland net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share € | 5.80 | 4.56 |
16.00% | 21.38% | |
P/E | 9.88 | |
EV/Sales | 2.01 |
9 Analysts have issued a ASR Nederland forecast for earnings per share. The average ASR Nederland <a href=/blog/eps>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the ASR Nederland stock is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.